Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Sarcoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms 1

Interventions

Sorafenib 23Bevacizumab 11Radiosurgery 6Capecitabine 6Radiofrequency Ablation 5Oxaliplatin 5Fluorouracil 5Doxorubicin 5pembrolizumab 4Sunitinib 4Erlotinib Hydrochloride 4Cisplatin 4Ramucirumab 3Radiotherapy 3Nivolumab 3Leucovorin 3Carboplatin 3tremelimumab 2spartalizumab 2perflutren 2derazantinib 2carotuximab 2Mitomycin 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Immunohistochemistry 2Gemcitabine 2Folfox protocol 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liver Neoplasms × fluoromisonidazole × Clear all
NCT02471313 2019-04-23

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
3 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡